Serina Therapeutics, Inc.
SER- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001708599
No open-market purchases or sales by Serina Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $2.73M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 2:01 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $19.2M (14755.4% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 25, 2026 | Jan 6, 2025 | Mar 22, 2024 | Mar 31, 2023 | Mar 29, 2022 |
| Revenue | $130.0K | $56.0K | $142.0K | $34.0K | $144.0K |
| Cost of revenue | – | – | $40.0K | $13.0K | $19.0K |
| Gross profit | – | – | $102.0K | $21.0K | $125.0K |
| Operating expenses | $24.2M | $17.1M | $10.1M | $7.00M | $8.16M |
| Research and development | $13.2M | $7.48M | $734.0K | $1.02M | $1.46M |
| Selling, general and administrative | $11.0M | $9.62M | $9.33M | $5.97M | $6.71M |
| Operating income | -$24.0M | -$17.0M | -$9.89M | -$6.97M | -$7.93M |
| Interest expense | – | – | $4.90M | $3.33M | – |
| Income tax | $18.0K | $0 | – | – | – |
| Net income | -$19.2M | -$11.1M | -$14.8M | -$10.5M | -$8.68M |
| EPS, basic | $-1.91 | $-1.51 | $-13.72 | $-0.28 | – |
| EPS, diluted | $-1.91 | $-1.51 | $-13.72 | – | – |
| Weighted shares, basic | 10.2M | 7.36M | 1.08K | 37.9M | – |
| Weighted shares, diluted | 10.2M | 7.36M | 1.08K | – | – |
| Margins and growth | |||||
| Gross margin | – | – | 71.8% | 61.8% | 86.8% |
| Operating margin | -18478.5% | -30442.9% | -6962.7% | -20514.7% | -5509.0% |
| Net margin | -14755.4% | -19894.6% | -10424.6% | -30770.6% | -6024.3% |
| Revenue growth, year over year | +132.1% | −60.6% | +317.6% | −76.4% | −92.3% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 25, 2026 | Jan 6, 2025 | Mar 22, 2024 | Mar 31, 2023 | Mar 29, 2022 |
| Cash and equivalents | $3.06M | $3.67M | $345.0K | $645.0K | $584.0K |
| Accounts receivable | – | – | $57.0K | $4.00K | $25.0K |
| Total current assets | $6.08M | $5.68M | $754.0K | $2.45M | $2.23M |
| Property, plant and equipment | $465.0K | $501.0K | – | – | – |
| Intangible assets | – | – | $607.0K | $738.0K | $870.0K |
| Total assets | $6.95M | $6.72M | $12.0M | $3.24M | $3.15M |
| Accounts payable | $1.93M | $744.0K | $1.41M | $568.0K | $193.0K |
| Total current liabilities | $3.56M | $2.37M | $5.91M | $10.1M | $8.97M |
| Long-term debt | – | – | – | $18.1M | – |
| Total liabilities | $6.99M | $6.22M | $6.61M | $20.6M | $15.0M |
| Shareholders' equity | -$37.0K | $508.0K | $5.36M | -$17.3M | -$11.9M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 25, 2026 | Jan 6, 2025 | Mar 22, 2024 | Mar 31, 2023 | Mar 29, 2022 |
| Operating cash flow | -$18.0M | -$17.1M | -$7.80M | -$5.94M | -$7.86M |
| Capital expenditures | $59.0K | $22.0K | – | – | – |
| Free cash flow | -$18.0M | -$17.2M | – | – | – |
| Depreciation and amortization | $100.0K | $194.0K | – | – | – |
| Stock-based compensation | $3.79M | $2.60M | $648.0K | $760.0K | $999.0K |
| Investing cash flow | -$59.0K | -$22.0K | -$10.0M | – | $666.0K |
| Financing cash flow | $17.4M | $13.2M | $17.5M | $6.00M | $7.25M |
| Net change in cash | -$616.0K | -$3.95M | -$300.0K | $61.0K | $57.0K |
| Ratio | |||||
| Stock-based compensation, % of revenue | 2917.7% | 4633.9% | 456.3% | 2235.3% | 693.8% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Aug 10, 2026 | 25.4M | +147.8% | SEC |
| May 10, 2026 | 15.0M | +50.5% | SEC |
| Mar 18, 2026 | 12.3M | +24.0% | SEC |
| Nov 10, 2025 | 10.7M | +19.9% | SEC |
| Aug 8, 2025 | 10.3M | +15.4% | SEC |
| May 6, 2025 | 9.97M | +18.5% | SEC |
| Mar 20, 2025 | 9.93M | +297.2% | SEC |
| Nov 7, 2024 | 8.89M | −76.6% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-35 in Q1 2024.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.